Sickle Cell Disease Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2015 to 2020 and Forecast 2021 to 2027

$ PRICE - $ 3,000.00$ 8,900.00

Global Sickle Cell Diseases Treatment Market by Disease Type (Sickle Beta Thalassemia, Sickle Haemoglobin C Disease, Sickle Cell Anaemia, Others), by Therapy (Bone Marrow Transplant, Blood Transfusion, Gene Therapy), by Drug Class (Antibiotics, Analgesics, Antimetabolite (Hydroxyurea), Others), by End user, (Hospitals, Retail Pharmacies, Others) and Geography

 

$ PRICE - $ 3,000.00$ 8,900.00
Clear selection
Clear
$ PRICE - $ 3,000.00$ 8,900.00
FacebookTwitterLinkedinEmail

Report

Description

The global sickle cell disease treatment market size valued USD 2.72 billion in 2020 and expected to reach USD 7.62 billion by 2027, at a CAGR of 14.09% during the forecast period 2021-2027. Drastic reduction of total RBC count is called as anaemia. It is also defined as the inability of carrying the appropriate amounts of oxygen by blood. Sickle cell diseases are the type of blood disorders which are genetically inherited. Sickle-cell anaemia is the common type of SCD in which sickle-shaped cell is formed. Generally, sickle cell disease starts taking shape at the early age i.e., within a year after birth which leads to several health issues like attacks of pain which are also called as the sickle-cell crisis, limbs swelling, bacterial infections etc. Chronic pain can be developed along with the age. Sickle-cell diseases arise when an individual inherited by abnormal copies of Hg gene from each parent. Burgeoning prevalence of sickle cell disease has expected to drive the market. As per Centre for Disease Control and Prevention, in 2016, about 100,000 individuals in U.S. are affected by the sickle cell diseases. Black or the African Americans are commonly more susceptible to sickle cell diseases. One in thirteen babies who belongs to the black race are born with SCD’s. Researchers have moved ahead to treat SCD by antibiotics to genome level. Researchers from the Stanford School of Medicine corrected the genes successfully which are carrying a gene for SCD and transplanted them with the healthy cells. With the help of Clustered Regularly Interspaced Short Palindromic Repeat technique (CRISPR), researchers have replaced the SCD cell genes with one which doesn’t carry those genes. In 2016, Infosys has donated USD 1.11 million for the stem cell research to develop gene therapies for the disorders like haemophilia and sickle cell disease.

Sickle Cell Disease Treatment Market

MARKET SUMMARY
-
14.09% CAGR
  • Study Period– 2021 – 2027
  • Base Year– 2020
  • CAGR– 14.09%
  • Largest Market– Asia-Pacific
  • Fastest Growing Market– North America

Sickle Cell Disease Treatment Market

  • The report on global sickle cell disease treatment market gives historical, current and future market sizes (US$ Bn) based on disease type, therapy, drug class, end user and region.
  • sickle cell disease treatment market report gives comprehensive outlook across the region with special emphasis on key regions such as North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
Key Players
  • Biogen
  • Gamida Cell
  • Genetix Pharmaceuticals Inc.
  • Sangamo Biosciences
  • Acceleron Pharma
  • Emmaus Medical, Inc.
  • Novartis AG
Sickle Cell Disease Treatment Market

Drivers And Restraints

Sickle Cell Diseases Treatment Market is driven by the increasing prevalence of sickle cell anaemia in the developed, developing as well as underdeveloped economies. In addition to this unmet needs are highly available, a rise in product pipelines for the treatment of SCD is anticipated to pose great demand for the market. Sickle cell disease treatment market is propelled by rising support by the regulatory bodies and government in the form of investments, fast-track approvals for the discovery of newer treatments. Sickle cell anaemia treatment market is restrained by slow adoption of treatments due to the cost associated with it, the absence of a permanent cure for this disease and complications associated with treatment.


North-America got significant share

Sickle Cell Disease Treatment Market

Based on the geographical regions, a global Sickle Cell Diseases Treatment Market is segmented into Latin America, Europe, North America, the Middle East and Africa, and Asia Pacific. North America is dominating the sickle cell anaemia treatment market due to the increase in activities in R&D, high accessibility of developed healthcare infrastructure and high reimbursement policies are attributing for the growth of the SCD treatment market in the region. Owing to the high prevalence rate of disease in Asia Pacific and African regions is favouring the growth of SCD treatment market. Asia-Pacific is one of the speedy growing markets due to the funding of the various industry players for stem cell research

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Notable Market Developments

  • In July 2017, Emmaus Medical Inc. Endari (L-glutamine oral powder) received U.S. FDA approval to treat the patients with age of five years and older having sickle cell disease
  • In 2016 Novartis AG acquired Selexys Pharmaceuticals in order to expand product offerings related to blood disorders and diseases

Key

Report Outline

Sickle Cell Disease Treatment Market Segmentation


Location

GEOGRAPHY


Report

Table Of Content

  1. Executive summary
  2. Global Sickle Cell Disease Treatment Market Introduction
    • Global Sickle Cell Disease Treatment Market– Taxonomy
    • Global Sickle Cell Disease Treatment Market–Definitions
      • Disease Type
      • Therapy
  1. Global Sickle Cell Disease Treatment Market Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Global Sickle Cell Disease Treatment Market Dynamics – Factors Impact Analysis
    • Global Sickle Cell Disease Treatment Market– Recent Market Introductions
  2. Global Sickle Cell Disease Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market Oppurtunity Analysis
  3. Global Sickle Cell Disease Treatment Market Forecast, By Diseases Type, 2013 – 2017 and Forecast, 2018 – 2024
    • Sickle Beta Thalassemia
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Sickle Haemoglobin C Disease
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Sickle Cell Anaemia
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Sickle Cell Disease Treatment Market Forecast, By Therapy, 2013 – 2017 and Forecast, 2018 – 2024
    • Bone Marrow Transplant
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Blood Transfusion
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Gene Therapy
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Sickle Cell Disease Treatment Market Forecast, By Drug Class, 2013 – 2017 and Forecast, 2018 – 2024
    • Antibiotics
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Analgesics
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Antimetabolites
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Sickle Cell Disease Treatment Market Forecast, By End User, 2013 – 2017 and Forecast, 2018 – 2024
    • Hospitals
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Retail Pharmacies
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Sickle Cell Disease Treatment Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024
    • North America
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Europe
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia-Pacific
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Latin America
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Middle East and Africa
      • Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Global Sickle Cell Disease Treatment Market- Opportunity Analysis Index – By Diseases Type, By Therapy, By Drug Class, By End User, and Region, 2018 – 2024
  2. North America Sickle Cell Disease Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Diseases Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Sickle Beta Thalassemia
      • Sickle Haemoglobin C Disease
      • Sickle Cell Anaemia
      • Others
    • Therapy Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Bone Marrow Transplant
      • Blood Transfusion
      • Gene Therapy
    • Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Antibiotics
      • Analgesics
      • Antimetabolite (Hydroxyurea)
      • Others
    • End User Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospitals
      • Diagnostic Centres
      • Blood Donation Centres
    • Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • US.
      • Canada
    • North America Sickle Cell Disease Treatment Market- Opportunity Analysis Index – By Diseases Type, By Therapy, By Drug Class, By End User, and Country, 2018 – 2024
    • North America Sickle Cell Disease Treatment Market Dynamics – Trends
  3. Europe Sickle Cell Disease Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Diseases Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Sickle Beta Thalassemia
      • Sickle Haemoglobin C Disease
      • Sickle Cell Anaemia
      • Others
    • Therapy Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Bone Marrow Transplant
      • Blood Transfusion
      • Gene Therapy
    • Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Antibiotics
      • Analgesics
      • Antimetabolite (Hydroxyurea)
      • Others
    • End User Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospitals
      • Diagnostic Centres
      • Blood Donation Centres
    • Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Russia
      • Poland
      • Rest of Europe
    • Europe Sickle Cell Disease Treatment Market- Opportunity Analysis Index – By Diseases Type, By Therapy, By Drug Class, By End User, and Country, 2018 – 2024
    • Europe Sickle Cell Disease Treatment Market Dynamics – Trends
  4. Asia-Pacific Sickle Cell Disease Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Diseases Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Sickle Beta Thalassemia
      • Sickle Haemoglobin C Disease
      • Sickle Cell Anaemia
      • Others
    • Therapy Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Bone Marrow Transplant
      • Blood Transfusion
      • Gene Therapy
    • Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Antibiotics
      • Analgesics
      • Antimetabolite (Hydroxyurea)
      • Others
    • End User Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospitals
      • Diagnostic Centres
      • Blood Donation Centres
    • Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn),
  5. Y-o-Y Growth (%), and Market Share (%)
    • Japan
    • China
    • India
    • ASEAN
    • Australia & New Zealand
    • Rest of Asia-Pacific
  • Asia-Pacific Sickle Cell Disease Treatment Market- Opportunity Analysis Index – By Diseases Type, By Therapy, By Drug Class, By End User, and Country, 2018 – 2024
  • Asia-Pacific Sickle Cell Disease Treatment Market Dynamics – Trends
  1. Latin America Sickle Cell Disease Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Diseases Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Sickle Beta Thalassemia
      • Sickle Haemoglobin C Disease
      • Sickle Cell Anaemia
      • Others
    • Therapy Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Bone Marrow Transplant
      • Blood Transfusion
      • Gene Therapy
    • Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Antibiotics
      • Analgesics
      • Antimetabolite (Hydroxyurea)
      • Others
    • End User Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospitals
      • Diagnostic Centres
      • Blood Donation Centres
    • Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Brazil
      • Mexico
      • Argentina
      • Venezuela
      • Rest of Latin America
    • Latin America Sickle Cell Disease Treatment Market- Opportunity Analysis Index – By Diseases Type, By Therapy, By Drug Class, By End User, and Country, 2018 – 2024
    • Latin America Sickle Cell Disease Treatment Market Dynamics – Trends
  2. Middle East & Africa Sickle Cell Disease Treatment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024
    • Diseases Type Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Sickle Beta Thalassemia
      • Sickle Haemoglobin C Disease
      • Sickle Cell Anaemia
      • Others
    • Therapy Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Bone Marrow Transplant
      • Blood Transfusion
      • Gene Therapy
    • Drug Class Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Antibiotics
      • Analgesics
      • Antimetabolite (Hydroxyurea)
      • Others
    • End User Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospitals
      • Diagnostic Centres
      • Blood Donation Centres
    • Country Analysis (2013 – 2017) and Forecast (2018 – 2024) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Gulf Cooperation Council (GCC) Countries
      • Israel
      • South Africa
      • Rest of MEA
    • MEA Sickle Cell Disease Treatment Market- Opportunity Analysis Index – By Diseases Type, By Therapy, By Drug Class, By End User, and Country, 2018 – 2024
    • MEA Sickle Cell Disease Treatment Market Dynamics – Trends
  3. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • Biogen (U.S.)
      • Gamida Cell (Israel)
      • Genetix Pharmaceuticals Inc. (U.S.)
      • Sangamo Biosciences (U.S.)
      • Alnylam Pharmaceuticals, Inc. (U.S.)
      • Acceleron Pharma (U.S.)
      • Global Blood Therapeutics Inc. (U.S.)
      • Emmaus Medical, Inc. (U.S.)
      • Novartis AG (Switzerland)
      • Bristol-Myers Squibb Company (U.S.).
  4. Research Methodology
  5. Key Assumptions and Acronyms

Report

Company Profile

  • Biogen (U.S.)
  • Gamida Cell (Israel)
  • Genetix Pharmaceuticals Inc. (U.S.)
  • Sangamo Biosciences (U.S.)
  • Alnylam Pharmaceuticals, Inc. (U.S.)
  • Acceleron Pharma (U.S.)
  • Global Blood Therapeutics Inc. (U.S.)
  • Emmaus Medical, Inc. (U.S.)
  • Novartis AG (Switzerland)
  • Bristol-Myers Squibb Company (U.S.)

Description

The global sickle cell disease treatment market size valued USD 2.72 billion in 2020 and expected to reach USD 7.62 billion by 2027, at a CAGR of 14.09% during the forecast period 2021-2027. Drastic reduction of total RBC count is called as anaemia. It is also defined as the inability of carrying the appropriate amounts of oxygen by blood. Sickle cell diseases are the type of blood disorders which are genetically inherited. Sickle-cell anaemia is the common type of SCD in which sickle-shaped cell is formed. Generally, sickle cell disease starts taking shape at the early age i.e., within a year after birth which leads to several health issues like attacks of pain which are also called as the sickle-cell crisis, limbs swelling, bacterial infections etc. Chronic pain can be developed along with the age. Sickle-cell diseases arise when an individual inherited by abnormal copies of Hg gene from each parent. Burgeoning prevalence of sickle cell disease has expected to drive the market. As per Centre for Disease Control and Prevention, in 2016, about 100,000 individuals in U.S. are affected by the sickle cell diseases. Black or the African Americans are commonly more susceptible to sickle cell diseases. One in thirteen babies who belongs to the black race are born with SCD’s. Researchers have moved ahead to treat SCD by antibiotics to genome level. Researchers from the Stanford School of Medicine corrected the genes successfully which are carrying a gene for SCD and transplanted them with the healthy cells. With the help of Clustered Regularly Interspaced Short Palindromic Repeat technique (CRISPR), researchers have replaced the SCD cell genes with one which doesn’t carry those genes. In 2016, Infosys has donated USD 1.11 million for the stem cell research to develop gene therapies for the disorders like haemophilia and sickle cell disease.

ASIA PACIFIC OFFICE

Precision Business Insights, 5th Floor, Mohan’s Elite, Opp : Bharat Petroleum Pump, Khanamet Road, Hitech City, Hyderabad – 500084

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX